New Research Says Combination Immunotherapy Should be First-Line Therapy for Patients with BRAF-mutant Melanoma
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 2 February 2022 In News, Science, Treatment
While all patients with advanced melanoma can be treated with checkpoint immunotherapies, patients with tumors containing the BRAF mutation can also be treated with targeted therapies. However, until now, doctors have had little prospective data to determine which treatment approach should be started first. A new study led by Dr. Michael Atkins provides practice-changing insight.
Melanoma Mortality Rate Continues Decline Fueled by Treatment Advances
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 26 January 2022 In News, Prevention, Science, Treatment
Each January, the American Cancer Society (ACS) releases updated estimates about trends in new cancer cases and deaths in its annual report, Cancer Facts and Figures. This report highlights the estimated incidence (number of new cases), prevalence (number of people alive today with a history of cancer), and survival statistics for cancer in the United States.
MRA Celebrates Approval of Tebentafusp - First Drug for Metastatic Uveal Melanoma
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 26 January 2022 In News, Treatment
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, applauds the U.S. Food and Drug Administration (FDA) decision to approve the first-ever therapy for metastatic or unresectable uveal melanoma.
From Personal Loss to Professional Service
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 25 January 2022 In Allies & Partnerships, Melanoma Stories
Since 2009, O’Melveny & Myers (OMM), an internationally recognized law firm founded in 1885, has served as pro bono counsel for the Melanoma Research Alliance. Over the last decade, the firm has advised MRA leadership and represented the organization in many areas, including grant agreements, HR policies, tax issues, intellectual...
Registration Now Open for March 9 Patient Forum!
MRA’s Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on March 9, will bring together melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provide networking opportunities across the melanoma community.
Early Studies Suggest New Immune Checkpoint Target for Melanoma
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 6 January 2022 In Science
Checkpoint immunotherapies have revolutionized the way melanoma is treated. However, up to 50% of patients don’t respond or go on to develop resistance to even our latest approved therapies. Thankfully, researchers such as MRA-funded investigator Roberto Tinoco, PhD are hard at work discovering the next checkpoint inhibitors capable of revving up the immune system and fighting melanoma.
Championing Clinical Trials
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 2 January 2022 In Melanoma Stories, Science, Treatment
Too often, the first time someone is exposed to clinical trials is when they've been diagnosed with a serious, life threatening illness. Learn how Mary Elizabeth partnered with her doctor Jedd Wolchok to take back control from melanoma.
Advancing Rare Melanoma Research
27 December 2021 In Science
Despite the tremendous progress made in the last decade in treating melanoma, approximately one third of patients don’t benefit from currently approved therapies. This includes the majority of people with rare forms of melanoma. But as investigators continue to chip away at understanding what causes these melanomas and how they differ from UV-driven cutaneous melanomas, the hope is the better understanding they reap will be sown into improved treatments for these patients.
MRA Applauds Expanded Approval of Pembrolizumab to Patients with Stage 2 Melanoma
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 6 December 2021 In News, Science, Treatment
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to expand eligibility of Merck’s Keytruda (pembrolizumab) to include patients with Stage IIB and IIC melanoma.
One Family, One Community, One Goal: Cure Melanoma
Melanoma is personal for Kathy Mason, and positivity is a way of life since her son Ryan’s Stage 3 melanoma diagnosis at only 24-years old.